TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Clavién-Dindo grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Delayed Gastric Empty (DGE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postoperative pancreatic fistula (POPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Post pancreatectomy Hemorrhage (PPH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of subjects with changes in clinical laboratory values - Serum Chemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital signs: Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood oxygen level dependent (BOLD) responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensory pain responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional pain responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Depression and Anxiety of Survivors' and Caregivers'
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tissue quality assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with complete TMA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Process of Recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: perfusion defect percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CA 125 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PD-L1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total incidence of postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Consistency of neck masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extension of neck masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Definition of neck masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from target vessel instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anaerobic threshold change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change from baseline in EASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Success rate of the regional blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ADHD-RS-5 symptoms total raw score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient attitudes towards utility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient empathy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite of Major cardiovascular event or major adverse limb event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac Output (L/min) area under curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative energy deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of severe and moderate events
Endpoint domain: Adverse events/effects
Primary endpoint: Retinal structural changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-intubation sore throat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting a Score of 4 or 5 on Intention to Use Teacher STAC Strategies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cough & sputum assessment questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Uptake of genetic counseling risk recommendations by the participant
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Uptake of genetic testing recommendations by the provider
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Residual urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference in the Area Under the Curve (AUC) of Interleukin-6 (IL-6) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite outcome of postoperative serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of neonates who survive until initial hospital discharge
Endpoint domain: Mortality/survival
Primary endpoint: Skin breakdown protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of participants with treatment-related serious adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Target area hair count of non-vellus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants experiencing local and systemic reactions within 7 days of each study injection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants experiencing unsolicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of physician-assisted adverse events considered related to any of the study injections
Endpoint domain: Adverse events/effects
Primary endpoint: Career Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ureteral stricture length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Intrahepatic triglyceride (IHTG) content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in de novo lipogenesis (DNL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in glucose, free fatty acid and triglyceride levels in response to a meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metagenomic microbiome profile comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial gene expression profile comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proteomic profile assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OHI status and Plaque index assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stunting (Height/Length for age Z scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autonomic data including pre-ejection period and respiratory sinus arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in FACT-Neurotoxicity subscale (NtxS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Elapsed time with SpO2 above 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of treatment-emergent adverse events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Death or bronchopulmonary dysplasia (BPD)
Endpoint domain: Mortality/survival
Primary endpoint: Self-Reported Sleep Quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: prevalence of full stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: EWL% at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from SAEs and SADEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mid-thigh skeletal muscle area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Efficacy of protection against infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Efficacy of protection against severe disease manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parents' perception of teething signs and symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Endogenous glucose production during fasting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Tumour-to-dose limiting organ dose ratio T-to-bone marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tumour-to-dose limiting organ dose ratio T-to-kidney
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of treatment safety by number of AEs graded according to CTCAE v5.0
Endpoint domain: Adverse events/effects
Primary endpoint: B cell and T cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Primary endpoint: Forced vital capacity percent predicted (FVCpp)
Endpoint domain: Physiological/clinical
Primary endpoint: Change in bone volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Free and Cued Selective Reminding Test (FC-SRT) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mini-Mental State Examination 2 (MMSE-2) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Activities of Daily Living for Mild Cognitive Impairment (ADCS-ADLPI) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cognitive function as measured by ADAS-Cog 13
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: proportion of reoperations
Endpoint domain: Adverse events/effects
Primary endpoint: Tissue distribution of 68Ga-NY104
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to t of minzasolmin tablets under fasted conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from zero to infinity of minzasolmin tablets under fasted conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of minzasolmin tablets under fasted conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pupillary Pain Index measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Satisfaction at 1 year
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety of tovorafenib
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of tovorafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of tovorafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of trained radiologists
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ACR50 Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of 4F-PCC
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of 4F-PCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance of vertical jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power of vertical jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 100 meter sprint performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-infectious fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain, Enjoyment of Life and General Activity scale (PEG)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of participants reporting solicited administration site events within 7 days after the first vaccine dose
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants reporting unsolicited adverse events (AEs) within 28 days after the first vaccine dose
Endpoint domain: Adverse events/effects
Primary endpoint: Breast Pain Visual Analog Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength and power of trunk and shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle endurance of trunk and shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in balance ability as measured by the BESTest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipopolysaccharide (LPS) level of Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Microbiota Level in Stool sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oxygen Saturation (SpO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under ROC curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ablation volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Thermal ablation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pressure pain detection threshold assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal pain and strength in isometric shoulder external rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of Oral Anticoagulation Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Length of Duration for Oral Anticoagulation Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants who test positive for COVID-19
Endpoint domain: Adverse events/effects
Primary endpoint: Serum COVID-19 T-cell specific immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Virus-neutralizing capacity of SARS-CoV-2 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Enrollment Rate of Participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of Intervention Measure Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant Review Rate of Action Plan
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pregnancy-Specific Nausea and Vomiting Severity Scale (PUQE-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in CDASI-A score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Blood triglyceride levels (fasting)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Blood triglyceride levels (postprandial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Satisfaction with the app
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of cardioversion at 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total score of Montgomery Asperger Depression Scale (MADRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta QTc length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delta neutrophil activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the Edinburgh Postnatal Depression Scale (EPDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference between first systolic BP and average of 3 systolic BPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference between first diastolic BP and average of 3 diastolic BPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Graft mean blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pulsatility of graft vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic filling of the graft vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Head circumference (HC) velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with obesity related comorbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate to Vigorous Physical Activity (Minutes/Week)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive impairment change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Activities of daily living performance change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Depression level change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Involuntary Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GAD 7 Diagnostic Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in EORTC Quality of Life Questionnaire (QLQ)-C30 General Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in EuroQol (EQ)-five dimensions (5D)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of brain metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Adherence Performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Detection rate of 18F-FACBC PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from visual acuity at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Objective Scatter Index at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Contrast Sensitivity at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bowel incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Infarct progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of fiberoptic intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean number of sessions attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Axial length growth of the eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until medically ready for discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WBC characterisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Completion of transplant evaluation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in Measures of Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in expression of nasal mucosal inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum jump strength changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage difference of lowest mean arterial blood pressure from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Expression of JAK-STAT pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: POCUS Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of different sleep stages
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Absolute amount of nocturnal urinary catecholamine excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of HCV RNA positive participants who achieve a Sustained Virological Response at 12 weeks (SVR12) after treatment completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability and helpfulness of program components
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of subjects screened for hyperlipidemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of subjects who initiated a statin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes